Senseonics assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Sean Lee assumed coverage of Senseonics (SENS) with a Buy rating and $1.10 price target The company has the only 365-day continuous glucose monitoring system on the market, the analyst tells investors in a research note. The firm says Senseonics is believed to be the fourth largest provider of continuous glucose monitoring systems in the U.S. The company’s flagship product is Eversense 365, which is the first and so far only approved CGM system that lasts for 12 months, compared to 7-15 days for traditional CGMs, contends H.C. Wainwright.